Skip to content

Determining the value of a test named Gated SPECT MPI for determining blood supply reduction to guide the angioplasty procedure of a heart vessel which is innocent in causing heart attack in heart attack patient who have undergone emergency angioplasty and have more than one heart vessel diseased.

Value of Gated-SPECT MPI for Ischemia-Guided PCI of non-culprit vessels in STEMI Patients with Multivessel Disease after primary PCI

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015384
Enrollment
100
Registered
2018-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ST Elevation Myocardial Infarction (STEMI) patients with multivessel disease who have undergone Primary PCI to culprit vessel only.

Interventions

Intervention1: Gated SPECT MPI test: Gated SPECT MPI test for detection of ischemia to guide for staged post-primary PCI in non-culprit vessel. Control Intervention1: Coronary Angiogram: Coronary Ang

Sponsors

International Atomic Energy Agency IAEA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: STEMI patients with a multivessel CAD over 18 years old, stable hemodynamically, who received a primary PCI (target vessel revascularization only) during the first 12 hours after the initial pain episode Non-culprit coronary stenosis >=70% (as determined by the interventional cardiologist performing the index primary PCI), in vessels with >= 2.5 mm diameter Written informed consent

Exclusion criteria

Exclusion criteria: Patients with atrial fibrillation or flutter, or any other condition (such as LV thrombus), which may mandate the use of oral anticoagulation Patients in cardiogenic shock Patient with a major coexisting illness affecting survival less than one year Pregnancy or breast-feeding Previous STEMI, CABG or PCI Severe asthma or CPOD Inability to understand and sign an informed consent

Design outcomes

Primary

MeasureTime frame
Comparison of Ischemia severity between the two arms at one year of follow-up, as defined by the difference in percent ischemic myocardiumTimepoint: One year follow-up

Secondary

MeasureTime frame
MACE (death, MI, urgent revascularization) Hospitalization for ischemia or heart failure Symptomatic ischemia Timepoint: During the period of one year follow-up

Countries

India

Contacts

Public ContactDr G Karthikeyan

All India Institute of Medical Sciences, New Delhi

karthik2010@gmail.com01126594464

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 11, 2026